Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

ABL Bio Inc. unveils clinical results for bispecific immuno-oncology candidates ...

26 October 2026 · By · Wire by Fusion42

Published

26 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at en.fnnews.com →

◆ Verified

Fusion42 · 26 October 2026 · Fusion42 review

ABL Bio Inc. disclosed promising clinical results for its bispecific immuno-oncology drugs Givastomig and Ragistomig, including high response rates and manageable safety profiles, and is advancing their development with the FDA for Phase 3 trials and combination therapies.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have fresh openings in immuno-oncology trial designs and partnerships with the FDA in the US. Givastomig’s strong Phase 1b results and Ragistomig’s dosing advances offer you routes for faster combination therapies beyond PD-(L)1 resistance.

◆ Coverage

1 source · 26 Oct 2026

◆ Related on Wire

◆ Topics

Biotechimmuno-oncologyclinical-trialsfda-approvalbispecific-antibodiescancer-treatment